TSHA · Taysha Gene Therapies, Inc.

Track TSHA — free

$4.63 -0.11 (-2.32%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.52B

325.83M

Volume · Oct 2 2.56M Avg daily vol (3M) 3.16M

Up next

Latest filing: 10-Q

filed Aug 11, 2026

Q2 2026 earnings call transcript

call held Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$5.49M

Trailing 12 months

Net income (TTM)

−$149.63M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-2,792.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$406.15M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+23.8%

Year over year · more shares

Price change (1Y)

+49.1%

Trailing year

Short interest

15.8%

Latest settlement · 18.8 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −13%

below

Price vs 50-day avg −16%

below

RSI (14) 35

neutral

MACD trend Positive

52-week position 41%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −16%

trailing

6-month return +6%

trailing

YTD return −14%

this year

Relative strength −7%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $5 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +40 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

15.78% of float · ▲ +9.8% MoM · 18.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Strong

Revenue growth +17%

Y/Y

EPS growth +6%

Y/Y

Free cash flow $-93.8M

Balance sheet $49.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 89%

annualized · 1-yr

Max drawdown −33%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 14, 2023

Private placement gross proceeds · PIPE closing $150M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−13% Bearish

Price vs 50-day avg

−16% Bearish

RSI (14)

35 Neutral

MACD trend

Positive Bullish

52-week position

41% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $6 › 200d $5 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +40 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

15.78% of float · ▲ +9.8% MoM · 18.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $5 · 41% Range high $7

vs 200-day avg -13% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TSHA Taysha Gene Therapies, Inc. this stock	$1.52B	-13.8%	+17.3%	—	15.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+540.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

208

% held: 92.2%
Net QoQ: +34.5M sh
Top holder: Avoro Capital Advisors LLC

Held Float

View

Held by Funds

Fund positions

170

View

Short & Settlement

Short Interest Rising

Shares short

51.4M

Days to cover: 18.8d
Change: +4.6M sh

View

Short Volume

Short vol %

69%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

505

Value: $2.8K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

48.9%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$9.8M

Net income (FY): $-109.0M
EPS diluted: $-0.34

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 13

View

Proposed Sales

Value

$1.3M

Shares: 200.0K
Filed: Jul 10, 2026

View

Exempt Offerings

Offering

$150.0M

Filed: Aug 25, 2023

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
TSHA	-1.0%	-16.0%	+5.6%	-2.7%	-13.8%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	-0.6%	-15.8%	-6.9%	-2.9%	-25.9%

Key facts CIK 1806310 CUSIP 877619106 13F (30d) 5 filings 5 filers Visit website Investor relations

TSHA · Taysha Gene Therapies, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance